Next, to understand the alterations in the TME following the activation of innate immunity, we investigated the effects of enhancing anti-tumor immunity by using a STING agonist (BMS-986301) in the ICB-responsive RIL-175 murine HCC model in C57Bl/6 mice. This evidence concerns the gene STING1 and neoplasm.